BioInvent receives IND approval for Phase I/IIa trial of anti-TNFR2 antibody BI-1808 |
| April 07, 2021 | April 2021 Bond Updates |
|
LUND, Sweden, April 7, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) for the Phase I/IIa clinical study of the immuno-modulatory... |
| View more at: https://www.prnewswire.com:443/news-releases/bioinvent-receives-ind-approval-for-phase-iiia-trial-of-anti-tnfr2-antibody-bi-1808-301263794.html |
| Related News |
|